Linagliptin as add-on therapy to insulin for patients with type 2 diabetes

References

• McGillJBSloanLNewmanJLong-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled studyDiabetes Care201336223724423033241
   PubMed Web of Science ®Google Scholar
• BarnettAHHuismanHJonesRvon EynattenMPatelSWoerleHJLinagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trialLancet Epub2013813
   PubMed Web of Science ®Google Scholar
• Yki-JarvinenHRosenstockJDuran-GarciaSEffects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥ 52-week randomized, double-blind studyDiabetes Care2013 Epub2013923
   Google Scholar
• SarwarNGaoPSeshasaiSREmerging Risk Factors CollaborationDiabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesLancet201037597332215222220609967
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionNational Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States 2011Atlanta, GAUS Department of Health and Human Services, Centers for Disease Control and Prevention2011 Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdfAccessed July 11, 2013
   Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2013Diabetes Care201336Suppl 1S11S6623264422
   PubMed Web of Science ®Google Scholar
• BaggioLLDruckerDJBiology of incretins: GLP-1 and GIPGastroenterology200713262131215717498508
   PubMed Web of Science ®Google Scholar
• DruckerDJNauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet200636895481696170517098089
   PubMed Web of Science ®Google Scholar
• MentleinRGallwitzBSchmidtWEDipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumEur J Biochem199321438298358100523
   PubMedGoogle Scholar
• RodbardHWJellingerPSDavidsonJAStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic controlEndocr Pract200915654055919858063
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceType 2 Diabetes: Newer Agents for Blood Glucose Control in Type 2 DiabetesLondonNational Institute for Health and Clinical Excellence2009 Available from: http://www.nice.org.uk/nicemedia/pdf/CG87ShortGuideline.pdfAccessed May 29, 2013
   Google Scholar
• KahnSEHaffnerSMHeiseMAADOPT Study GroupGlycemic durability of rosiglitazone, metformin, or glyburide monotherapyN Engl J Med2006355232427244317145742
   PubMed Web of Science ®Google Scholar
• NicholsGAAlexanderCMGirmanCJKamal-BahlSJBrownJBTreatment escalation and rise in HbA1c following successful initial metformin therapyDiabetes Care200629350450916505496
   PubMed Web of Science ®Google Scholar
• BrownJBConnerCNicholsGASecondary failure of metformin mono-therapy in clinical practiceDiabetes Care201033350150620040656
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBAmerican Diabetes Association (ADA)European Association for the Study of Diabetes (EASD)Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• LiYXuWLiaoZInduction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell functionDiabetes Care200427112597260215504992
   PubMed Web of Science ®Google Scholar
• XuLManCDCharbonnelBEffect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approachDiabetes Obes Metab200810121212122018476982
   PubMed Web of Science ®Google Scholar
• NathanDMRoussellAGodineJEGlyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind studyAnn Intern Med198810833343403124685
   PubMed Web of Science ®Google Scholar
• AhrénBHolstJJMariACharacterization of GLP-1 effects on beta-cell function after meal ingestion in humansDiabetes Care200326102860286414514592
   PubMed Web of Science ®Google Scholar
• HolstJJChristensenMLundARegulation of glucagon secretion by incretinsDiabetes Obes Metab201113Suppl 1899421824261
   PubMed Web of Science ®Google Scholar
• JelsingJVrangNvan WitteloostuijnSBMarkMKleinTThe DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic miceJ Endocrinol2012214338138722761275
   PubMed Web of Science ®Google Scholar
• AkarteASSrinivasanBPGandhiSA novel long acting DPP-IV inhibitor PKF-275–055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic ratsBiochem Pharmacol201283224125222015634
   PubMed Web of Science ®Google Scholar
• BrazgRXuLDalla ManCCobelliCThomasKSteinPPEffect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetesDiabetes Obes Metab20079218619317300594
   PubMed Web of Science ®Google Scholar
• BosiETime for testing incretin therapies in early type 1 diabetes?J Clin Endocrinol Metab20109562607260920525907
   PubMed Web of Science ®Google Scholar
• BuseJBBergenstalRMGlassLCUse of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trialAnn Intern Med2011154210311221138825
   PubMed Web of Science ®Google Scholar
• CampbellRKClarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitusClin Ther201133551152721665040
   PubMed Web of Science ®Google Scholar
• MonamiMDicembriniIMartelliDMannucciESafety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trialsCurr Med Res Opin201127Suppl 3576422106978
   PubMed Web of Science ®Google Scholar
• diabetes.org [homepage on the Internet]ADA/EASD/IDF Statement concerning the use of incretin therapy and pancreatic disease [ADA news release]American Diabetes Association2013 [updated June 28, 2013; cited July 10, 2013]. Available from: http://www.diabetes.org/for-media/2013/recommendations-for.htmlAccessed September 25, 2013
   Google Scholar
• CryerPEHypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetesDiabetologia200245793794812136392
   PubMed Web of Science ®Google Scholar
• ChristensenMVedtofteLHolstJJVilsbøllTKnopFKGlucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humansDiabetes201160123103310921984584
   PubMed Web of Science ®Google Scholar
• AhrénBFoleyJEBosiEClinical evidence and mechanistic basis for vildagliptin’s action when added to metforminDiabetes Obes Metab201113319320321205107
   PubMed Web of Science ®Google Scholar
• HermansenKMortensenLSBodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitusDrug Saf200730121127114218035865
   PubMed Web of Science ®Google Scholar
• ScheenAJPharmacokinetics of dipeptidylpeptidase-4 inhibitorsDiabetes Obes Metab201012864865820590741
   PubMed Web of Science ®Google Scholar
• ThomasLEckhardtMLangkopfETadayyonMHimmelsbachFMarkM(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitorsJ Pharmacol Exp Ther2008325117518218223196
   PubMed Web of Science ®Google Scholar
• Tradjenta®(linagliptin) tablets [package insert]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals, Inc2011
   Google Scholar
• fda.gov [homepage on the internet]Tradjenta (linagliptin) Prescribing Information September 2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201280s005lbl.pdfAccessed October 9, 2013
   Google Scholar
• SchernthanerGBarnettAHEmserASafety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitusDiabetes Obes Metab201214547047822268497
   PubMed Web of Science ®Google Scholar
• DeaconCFHolstJJLinagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetesExpert Opin Investig Drugs2010191133140
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBAmerican Diabetes AssociationEuropean Association for Study of DiabetesMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care200932119320318945920
   PubMed Web of Science ®Google Scholar
• FonsecaVSchweizerAAlbrechtDBaronMAChangIDejagerSAddition of vildagliptin to insulin improves glycaemic control in type 2 diabetesDiabetologia20075061148115517387446
   PubMed Web of Science ®Google Scholar
• VilsbøllTRosenstockJYki-JärvinenHEfficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetesDiabetes Obes Metab201012216717720092585
   PubMed Web of Science ®Google Scholar
• BarnettAHCharbonnelBDonovanMFlemingDChenREffect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metforminCurr Med Res Opin201228451352322313154
   PubMed Web of Science ®Google Scholar
• BlechSLudwig-SchwellingerEGräfe-ModyEUWithopfBWagnerKThe metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humansDrug Metab Dispos201038466767820086031
   PubMed Web of Science ®Google Scholar
• DeaconCFDipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative reviewDiabetes Obes Metab201113171821114598
   PubMed Web of Science ®Google Scholar
• Graefe-ModyUFriedrichCPortAEffect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*)Diabetes Obes Metab2011131093994621672124
   PubMed Web of Science ®Google Scholar
• PlantingaLCCrewsDCCoreshJCDC CKD Surveillance TeamPrevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetesClin J Am Soc Nephrol20105467368220338960
   PubMed Web of Science ®Google Scholar
• FriedrichCEmserAWoerleH-JGraefe-ModyURenal Impairment Has No Clinically Relevant Effect on the Long-Term Exposure of Linagliptin in Patients With Type 2 DiabetesAm J Ther2013 Epub2013213
   PubMed Web of Science ®Google Scholar
• RussoEPennoGDel PratoSManaging diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptinDiabetes Metab Syndr Obes2013616117023650450
   PubMedGoogle Scholar
• ChapelskyMCThompson-CulkinKMillerAKSackMBlumRFreedMIPharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiencyJ Clin Pharmacol200343325225912638393
   PubMed Web of Science ®Google Scholar
• ChanJCScottRArjona FerreiraJCSafety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiencyDiabetes Obes Metab200810754555518518892
   PubMed Web of Science ®Google Scholar
• NowickiMRychlikIHallerHLong-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety studyInt J Clin Pract201165121230123921977965
   PubMed Web of Science ®Google Scholar
• MakRHImpact of end-stage renal disease and dialysis on glycemic controlSemin Dial20001314810740665
   PubMed Web of Science ®Google Scholar
• LukashevichVSchweizerAShaoQGroopPHKothnyWSafety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trialDiabetes Obes Metab2011131094795421733061
   PubMed Web of Science ®Google Scholar
• RiegTGerasimovaMMurrayFNatriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic miceAm J Physiol Renal Physiol20123037F963F97122832924
   PubMed Web of Science ®Google Scholar
• AlterMLOttIMvon WebskyKDPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathyKidney Blood Press Res201236111913023171828
   PubMed Web of Science ®Google Scholar
• GroopPHCooperMPerkovicVEffects of the DPP-4 inhibitor linagliptin on albuminuria in patients with type 2 diabetes and diabetic nephropathyAbstract and poster presented at the 72nd Scientific Sessions of the American Diabetes AssociationJune 8–12; 2012Philadelphia, PA
   Google Scholar
• Boehringer Ingelheim PharmaceuticMARLINA: efficacy, safety and modification of albuminuria in type 2 diabetes subjects with renal disease with linagliptin Available from: http://www.clinicaltrials.gov/ct2/show/NCT01792518. NLM identifier: NCT01792518Accessed May 29, 2013
   Google Scholar
• Fagot-CampagnaABourdel-MarchassonISimonDBurden of diabetes in an aging population: prevalence, incidence, mortality, characteristics and quality of careDiabetes Metab200531 Spec No 2S535S552
   Web of Science ®Google Scholar
• BoothGLKapralMKFungKTuJVRelation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort studyLancet20063689529293616815377
   PubMed Web of Science ®Google Scholar
• MatykaKEvansMLomasJCranstonIMacdonaldIAmielSAAltered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy menDiabetes Care19972021351419118760
   PubMed Web of Science ®Google Scholar
• AhrénBAvoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetesVasc Health Risk Manag2013915516323637538
   PubMedGoogle Scholar
• BauduceauBDoucetJBordierLGarciaCDupuyOMayaudonHHypoglycaemia and dementia in diabetic patientsDiabetes Metab201036Suppl 3S106S11121211731
   PubMed Web of Science ®Google Scholar
• WoehrleHJNeubacherDPatelSvon EynattenMSafety and efficacy of linagliptin plus basal insulin combination therapy in a vulnerable population of elderly patients (age ≥70 years) with type 2 diabetesPoster presented at the 48th Annual Meeting of the European Association for the Study of DiabetesOctober 1–5; 2012Berlin, Germany
   Google Scholar
• PatelSSchernthanerGBarnettAHEmserAvon EynattenMWoerleHJSafety and efficacy of linagliptin in elderly patients with type 2 diabetes: evidence from 1331 individuals aged ≥65 years [abstract]Diabetologia201255Suppl 1S351
   Google Scholar
• PaolissoGMonamiMMarfellaRRizzoMRMannucciEDipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?Adv Ther201229321823322411425
   PubMed Web of Science ®Google Scholar
• GoreMOMcGuireDKThe 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in contextDiab Vasc Dis Res200961535519156632
   PubMed Web of Science ®Google Scholar
• PatelAChalmersJPoulterNADVANCE: action in diabetes and vascular diseaseJ Hum Hypertens200519Suppl 1S27S3216075030
   PubMed Web of Science ®Google Scholar
• DuckworthWAbrairaCMoritzTVADT InvestigatorsGlucose control and vascular complications in veterans with type 2 diabetesN Engl J Med2009360212913919092145
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group; GersteinHCMillerMEByingtonRPEffects of intensive glucose lowering in type 2 diabetesN Engl J Med2008358242545255918539917
   PubMed Web of Science ®Google Scholar
• DesouzaCVBolliGBFonsecaVHypoglycemia, diabetes, and cardiovascular eventsDiabetes Care20103361389139420508232
   PubMed Web of Science ®Google Scholar
• NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med2007356242457247117517853
   PubMed Web of Science ®Google Scholar
• JørgensenCHGislasonGHAnderssonCEffects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention – a retrospective nationwide cohort studyCardiovasc Diabetol201095420843380
   PubMed Web of Science ®Google Scholar
• SimpsonSHMajumdarSRTsuyukiRTEurichDTJohnsonJADose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort studyCMAJ2006174216917416415461
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 DiabetesSilver Spring, MDUS Department of Health and Human Services2008 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdfAccessed September 25, 2013
   Google Scholar
• JohansenOENeubacherDvon EynattenMPatelSWoerleHJCardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programmeCardiovasc Diabetol201211322234149
   PubMed Web of Science ®Google Scholar
• von EynattenMGongYEmserAWoerleHJEfficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trialsCardiovasc Diabetol2013126023570327
   PubMed Web of Science ®Google Scholar
• GallwitzBRosenstockJRauchT2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trialLancet2012380984047548322748821
   PubMed Web of Science ®Google Scholar
• FrederichRAlexanderJHFiedorekFTA systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetesPostgrad Med20101223162720463410
   PubMed Web of Science ®Google Scholar
• Williams-HermanDEngelSSRoundESafety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetesBMC Endocr Disord201010720412573
   PubMed Web of Science ®Google Scholar
• SchweizerADejagerSFoleyJECouturierALigueros-SaylanMKothnyWAssessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes populationDiabetes Obes Metab201012648549420518804
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim PharmaceuticalsCAROLINA: cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes Available from: http://www.clinicaltrials.gov/ct2/show/NCT01243424?term=NCT01243424&rank=1. NLM identifier: NCT01243424Accessed May 29, 2013
   Google Scholar
• Takeda Global Research and Development Center, IncCardiovascular outcomes study of alogliptin in subjects with type 2 diabetes and acute coronary syndrome (EXAMINE) Available from: http://clinicaltrials.gov/ct2/show/NCT00968708?term=NCT00968708&rank=1. NLM identifier: NCT00968708Accessed May 29, 2013
   Google Scholar
• CobbleMEFrederichRSaxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular dataCardiovasc Diabetol201211622248301
   PubMed Web of Science ®Google Scholar
• Amylin Pharmaceuticals, LLCExenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus Available from: http://www.clinicaltrials.gov/ct2/show/NCT01144338?term=ExenatideStudyofCardiovascularEventLoweringTrial(EXSCEL)&rank=1. NLM identifier: NCT01144338Accessed May 29, 2013
   Google Scholar
• Novo NordiskLiraglutide effect and action in diabetes: evaluation of cardiovascular outcome results – a long term evaluation (LEADER®) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01179048?term=LiraglutideEffectandActioninDiabets(LEADER)&rank=1. NLM identifier: NCT01179048Accessed May 29, 2013
   Google Scholar
• BhattDLSAVOR TIMI 53 Steering Committee and InvestigatorsSaxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 studyPresented at the European Society of Cardiology CongressAugust 30–September 3; 2013Amsterdam, The Netherlands Available from: http://www.escardio.org/about/press/esc-congress-2013/press-conferences/Documents/slides/bhatt.pdfAccessed September 25, 2013
   Google Scholar
• HocherBSharkovskaYMarkMKleinTPfabTThe novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in ratsInt J Cardiol20131671879322217485
   PubMed Web of Science ®Google Scholar
• ChaykovskaLvon WebskyKRahnenführerJEffects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathyPLoS One2011611e2786122125632
   PubMed Web of Science ®Google Scholar
• ShahNDMullanRJBreslinMYawnBPTingHHMontoriVMTranslating comparative effectiveness into practice: the case of diabetes medicationsMed Care201048Suppl 6S153S15820473211
   PubMed Web of Science ®Google Scholar
• SpencerMSKiefferECSincoBRDiabetes-specific emotional distress among African Americans and Hispanics with type 2 diabetesJ Health Care Poor Underserved200617Suppl 28810516809877
   PubMed Web of Science ®Google Scholar
• DruckerDJBuseJBTaylorKDURATION-1 Study GroupExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyLancet200837296451240125018782641
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim PharmaceuticalsSafety and efficacy in type 2 diabetic patients with severe chronic renal impairment, 5 mg BI 1356 (Linagliptin) vs placebo, insulin background inclusive Available from: http://www.clinicaltrials.gov/ct2/show/NCT00800683?term=NCT00800683&rank=1. NLM identifier: NCT00800683Accessed May 29, 2013
   Google Scholar
• Boehringer Ingelheim PharmaceuticalsEfficacy and safety of linagliptin in elderly patients with type 2 diabetes Available from: http://www.clinicaltrials.gov/ct2/show/NCT01084005?term=NCT01084005&rank=1. NLM identifier: NCT01084005Accessed May 29, 2013
   Google Scholar
• BuseJBHenryRRHanJKimDDFinemanMSBaronADExenatide-113 Clinical Study GroupEffects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesDiabetes Care200427112628263515504997
   PubMed Web of Science ®Google Scholar
• LewinALipetzRWuJSchwartzSComparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III studyClin Ther200729584485517697903
   PubMed Web of Science ®Google Scholar
• ONGLYZA®(saxagliptin) tablets [package insert]Princeton, NJBristol-Myers Squibb2011
   Google Scholar
• JANUVIA®(sitagliptin) tablets [package insert]Whitehouse Station, NJMerck Sharp and Dohme Corp2006
   Google Scholar
• KothnyWFoleyJKozlovskiPShaoQGallwitzBLukashevichVImproved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitusDiabetes Obes Metab201315325225723039321
   PubMed Web of Science ®Google Scholar
• RosenstockJRendellMSGrossJLFleckPRWilsonCAMekkiQAlogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemiaDiabetes Obes Metab200911121145115219758359
   PubMed Web of Science ®Google Scholar
• InzucchiSENauckMvon EynattenMHehnkeUWoerleHJHenryRLower risk of hypoglycemia in elderly type 2 diabetes patients when linagliptin is added to basal insulin: an exploratory analysisPoster presented at the 73nd Scientific Sessions of the American Diabetes AssociationJune 21–25, 2013Chicago, IL
   Google Scholar
• AhrénBSchweizerADejagerSVildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetesJ Clin Endocrinol Metab20099441236124319174497
   PubMed Web of Science ®Google Scholar
• NauckMAHeimesaatMMBehleKEffects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteersJ Clin Endocrinol Metab20028731239124611889194
   PubMed Web of Science ®Google Scholar